The Experts below are selected from a list of 285 Experts worldwide ranked by ideXlab platform
Ellen K Wasan - One of the best experts on this subject based on the ideXlab platform.
-
A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Dawn Waterhouse, Marcel B Bally, Stuart Berger, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole. Methods Liposomal Econazole was prepared using a novel micelle exchange technique to incorporate the drug into the lipid bilayer of pre-formed liposomes using a poly(ethylene) glycol-linked phospholipid, distearoyl phosphatidylethanolamine (DSPE-PEG). This method allowed for stable and efficient drug incorporation into DPPC and DMPC liposomes at a final drug:lipid ratio of 0.05 ( w / w ) and increased solubility in saline from
-
a parenteral Econazole formulation using a novel micelle to liposome transfer method in vitro characterization and tumor growth delay in a breast cancer xenograft model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Stuart A Berger, Dawn Waterhouse, Marcel B Bally, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole.
Monici P Preti - One of the best experts on this subject based on the ideXlab platform.
-
treatment of dermatomycoses with topical fenticonazole and Econazole lokalbehandlung von dermatomykosen mit fenticonazol und econazol
Mycoses, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, Monici P PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of fenticonazole 2% cream or to Econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the fenticonazole group and only 13 from the included in the Econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of fenticonazole action was more rapid then that of Econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with fenticonazole and in 10 patients out of the 24 treated with Econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
E. M. Kokoschka - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Dermatomycoses with Topical Fenticonazole and Econazole/Lokalbehandlung von Dermatomykosen mit Fenticonazol und Econazol
Mykosen, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, P. Monici PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of fenticonazole 2% cream or to Econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the fenticonazole group and only 13 from the included in the Econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of fenticonazole action was more rapid then that of Econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with fenticonazole and in 10 patients out of the 24 treated with Econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
-
treatment of dermatomycoses with topical fenticonazole and Econazole lokalbehandlung von dermatomykosen mit fenticonazol und econazol
Mycoses, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, Monici P PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of fenticonazole 2% cream or to Econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the fenticonazole group and only 13 from the included in the Econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of fenticonazole action was more rapid then that of Econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with fenticonazole and in 10 patients out of the 24 treated with Econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
-
Treatment of dermatomycoses with topical fenticonazole and Econazole.
Mykosen, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, P. Monici PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of fenticonazole 2% cream or to Econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the fenticonazole group and only 13 from the included in the Econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of fenticonazole action was more rapid then that of Econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with fenticonazole and in 10 patients out of the 24 treated with Econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
Marcel B Bally - One of the best experts on this subject based on the ideXlab platform.
-
A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Dawn Waterhouse, Marcel B Bally, Stuart Berger, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole. Methods Liposomal Econazole was prepared using a novel micelle exchange technique to incorporate the drug into the lipid bilayer of pre-formed liposomes using a poly(ethylene) glycol-linked phospholipid, distearoyl phosphatidylethanolamine (DSPE-PEG). This method allowed for stable and efficient drug incorporation into DPPC and DMPC liposomes at a final drug:lipid ratio of 0.05 ( w / w ) and increased solubility in saline from
-
a parenteral Econazole formulation using a novel micelle to liposome transfer method in vitro characterization and tumor growth delay in a breast cancer xenograft model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Stuart A Berger, Dawn Waterhouse, Marcel B Bally, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole.
Dawn Waterhouse - One of the best experts on this subject based on the ideXlab platform.
-
A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Dawn Waterhouse, Marcel B Bally, Stuart Berger, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole. Methods Liposomal Econazole was prepared using a novel micelle exchange technique to incorporate the drug into the lipid bilayer of pre-formed liposomes using a poly(ethylene) glycol-linked phospholipid, distearoyl phosphatidylethanolamine (DSPE-PEG). This method allowed for stable and efficient drug incorporation into DPPC and DMPC liposomes at a final drug:lipid ratio of 0.05 ( w / w ) and increased solubility in saline from
-
a parenteral Econazole formulation using a novel micelle to liposome transfer method in vitro characterization and tumor growth delay in a breast cancer xenograft model
Pharmaceutical Research, 2006Co-Authors: Sebastian Cogswell, Stuart A Berger, Dawn Waterhouse, Marcel B Bally, Ellen K WasanAbstract:Purpose The purpose of this study was to develop a parenteral liposomal formulation of Econazole, a poorly water-soluble compound not previously available in an intravenous form. We are investigating Econazole as an anticancer agent based on its unique mechanism of action to which cancer cells are preferentially sensitive. An intravenous formulation of Econazole was desired for preclinical toxicity and efficacy studies of Econazole.
